Influenza myocarditis treated with antithymocyte globulin

Jenna A. Piccininni, Marc E. Richmond, Eva W. Cheung, Teresa M. Lee, Sabrina P. Law, Linda J. Addonizio, Warren A. Zuckerman

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Influenza is a cause of significant morbidity and mortality worldwide. Myocarditis is a rare complication of the virus and can vary widely in severity. The published cases of influenza B myocarditis in children tend to be severe with a high mortality rate. Current standard treatment of viral myocarditis is supportive care, although immunomodulatory therapies, such as steroids and intravenous immunoglobulin, are often used. T cells have been implicated in causing significant myocyte damage in myocarditis by leading to the downstream production of antibodies against viral and myocyte antigens; this has created a theoretical basis for the use of antithymocyte globulin to target T cells in these patients. We present a case of acute fulminant influenza B myocarditis in a pediatric patient that required mechanical circulatory support and improved only after treatment with antithymocyte globulin.

Original languageEnglish (US)
Article numbere20180884
Issue number5
StatePublished - Nov 2018
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Influenza myocarditis treated with antithymocyte globulin'. Together they form a unique fingerprint.

Cite this